Spanish CDMO invests €200k to protect clients' products

8 Feb 2018

Investment will enable Idifarma to both serialise commercial batches manufactured by them for clients and offer standalone serialisation services.

Spanish CDMO Idifarma has announced its plans to meet forthcoming EU serialisation regulations with a €200k investment.

Spanish CDMO invests €200k to protect clients' products
Idifarma's EU-GMP approved plant in Pamplona, Spain.

The investment will see the installation of the Antares Vision Print&Check EVO-TE carton serialisation station at its EU-GMP approved plant in Pamplona, Spain and comes ahead of the EU Falsified Medicines Directive’s (EU FMD) February 2019 deadline for the serialisation of licensed drug products.

Luis Oquiñena, general manager and co-founder of Idifarma said: “Recognising our role in combatting counterfeit medicines and supporting our customers with new regulatory requirements, we’ve taken a proactive approach and have been preparing for the arrival of this legislation for a long time now.

“We have worked closely with the manufacturers of this machine, and track and trace software vendors to specify our requirements according to our clients’ needs across the world.

“This machine offers us the flexibility to upgrade for future regulatory or client requirements and will enable us to help protect our clients’ products and the public against counterfeit pharmaceuticals.”

The company anticipates that the equipment will be operational six months ahead of the EU FMD deadline.

Oquiñena added: “Our investment will offer real support to our clients as they too prepare to meet the regulations. We will be able to serialise commercial batches manufactured by Idifarma for clients, but we will also be able to offer standalone serialisation services as an outsourcing partner.

“As the deadline draws closer we fully expect to see demand for these specialised outsourced services to increase.”

The investment in serialisation follows the expansion of its capsule filling capabilities in 2017 and strengthens Idifarma’s position as a specialised contract partner for the development and manufacturing of oral solid dosage forms, including high potency compounds and niche pharmaceuticals requiring small batches.

Read More

Related tags

Market News

Related news

Allergan to establish R&D presence in Cambridge, Massachusetts

Allergan to establish R&D presence in Cambridge, Massachusetts

10 Jan 2019

The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.

Read more 
Expedeon signs supply and license agreement for is Lightning-Link technology

Expedeon signs supply and license agreement for is Lightning-Link technology

9 Jan 2019

The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.

Read more 
Lilly to bag Loxo Oncology for $8 billion

Lilly to bag Loxo Oncology for $8 billion

8 Jan 2019

Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.

Read more 
Catalent to double its commercial biomanufacturing capacity

Catalent to double its commercial biomanufacturing capacity

7 Jan 2019

The $200-million expansion will support customers’ development programs and commercial launches.

Read more 
BMS and Celgene merge to create premier innovative biopharma company

BMS and Celgene merge to create premier innovative biopharma company

3 Jan 2019

Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

Read more 
Cambrex completes acquisition of Avista Pharma Solutions

Cambrex completes acquisition of Avista Pharma Solutions

2 Jan 2019

Acquisition adds a full complement of early-stage development capabilities to Cambrex’s larger scale capabilities for APIs and finished dosage forms.

Read more 
Novartis offers to acquire CellforCure

Novartis offers to acquire CellforCure

1 Jan 2019

Proposed acquisition will expand manufacturing capacity for innovative cell and gene therapies.

Read more 
BMS receives offer from Taisho to purchase UPSA

BMS receives offer from Taisho to purchase UPSA

30 Dec 2018

The potential transaction would position BMS to further refine its portfolio to focus on transformational medicines for patients facing serious diseases.

Read more 
Recipharm to potentially end operations in Ashton-under-Lyne facility

Recipharm to potentially end operations in Ashton-under-Lyne facility

24 Dec 2018

The operation has not been profitable for several years; no likely prospect of it being able to deliver an acceptable return in the medium term.

Read more 
An increased risk of a hard or ‘no deal Brexit?

An increased risk of a hard or ‘no deal Brexit?

24 Dec 2018

A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

Read more